Skip to content
UKUSA

Wolverine (BPC-157 + TB-500) Research Peptides

Compare Wolverine (BPC-157 + TB-500) research products by labelled quantity, price per mg, testing evidence and product transparency. See what’s available from suppliers and use our comparison tools to make more informed decisions.

Research-use products only. Not presented as supplements, medicines, or products for human or veterinary consumption.
8products compared
3labelled quantities
£2.00 – £9.00per mg
1with verified testing evidence

Top Picks

Best Overall

BPC-157 10mg + TB-500 10mgAscend Peptides UK

Why this score?
Testing & analytical evidence
39/45
Value
21/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
20 mg / vial
Testing evidence
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22
£2.50per mg
£49.99per pack
View AnalysisBuy Now
Product & testing details
Supplier
Ascend Peptides UK
Vials per pack
1
Price per vial
£49.99
Listing last checked
2026-09-22 11:39:13
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22

BPC-157 10mg + TB-500 10mg

Ascend Peptides UK
Why this score?
Testing & analytical evidence
39/45
Value
21/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Testing evidence
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22
£2.50per mg
£49.99per pack
View AnalysisBuy Now

Best Tested

BPC-157 10mg + TB-500 10mgAscend Peptides UK

Why this score?
Testing & analytical evidence
39/45
Value
21/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
20 mg / vial
Testing evidence
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22
£2.50per mg
£49.99per pack
View AnalysisBuy Now
Product & testing details
Supplier
Ascend Peptides UK
Vials per pack
1
Price per vial
£49.99
Listing last checked
2026-09-22 11:39:13
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22

BPC-157 10mg + TB-500 10mg

Ascend Peptides UK
Why this score?
Testing & analytical evidence
39/45
Value
21/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Testing evidence
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22
£2.50per mg
£49.99per pack
View AnalysisBuy Now

Lowest Price per mg

BPC-157 / TB-500 Mix 20mgReta Research

Why this score?
Testing & analytical evidence
12/45
Value
24/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
20 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
Supplied as a lyophilised 20mg blend, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK.
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£2.00per mg
£40.00per pack
View AnalysisBuy Now
Product & testing details
Supplier
Reta Research
Vials per pack
1
Price per vial
£40.00
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
Supplied as a lyophilised 20mg blend, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK.
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22

BPC-157 / TB-500 Mix 20mg

Reta Research
Why this score?
Testing & analytical evidence
12/45
Value
24/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
Supplied as a lyophilised 20mg blend, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK.
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£2.00per mg
£40.00per pack
View AnalysisBuy Now

Compare research products

Vial size
Research peptide product comparison
#ProductQuantityPrice / vialPrice / mgTestingScore
1BPC-157 10mg + TB-500 10mgAscend Peptides UK20 mg / vial£49.99per vial£2.50per mgTesting evidence
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
39/45
Value
21/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
2BPC-157 / TB-500 Mix 20mgReta Research20 mg / vial£40.00per vial£2.00per mgTesting evidence
Evidence status
Testing claimed
Manufacturer statement
Supplied as a lyophilised 20mg blend, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK.
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
12/45
Value
24/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
3Wolverine Stack 20mgPepSource20 mg / vial£60.00per vial£3.00per mgTesting evidence
Evidence status
Testing claimed
Manufacturer statement
Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity. Certificates are published per batch and searchable by lot code on our lab results page. This batch was independently tested by Janoshik Analytical.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
10/45
Value
18/25
Product identity
14/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
4Wolverine Stack 10mgPepSource10 mg / vial£40.00per vial£4.00per mgTesting evidence
Evidence status
Testing claimed
Manufacturer statement
"Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity"; "the certificate of analysis for the batch you receive is published on our lab results page"; "Purity: Verified by HPLC on every batch — the measured figure for your lot is published on its certificate of analysis"
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
10/45
Value
14/25
Product identity
14/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
5BPC-157 + TB-500 (Research Blend) — 10mgSPX Labs10 mg / vial£32.99per vial£3.30per mgTesting evidence
Evidence status
Testing claimed
Manufacturer statement
Analytical documentation available where testing has been performed; for batch SPX-BPCTB10-001 the site reports BPC-157 content 6.00 mg, TB-500 content 5.38 mg, and purity not reported.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
10/45
Value
17/25
Product identity
13/15
Supplier transparency
6/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
6BPC-157 + TB-500 Blend 10-mg / owsa-bb-10mgOwsa Labs10 mg / vial£29.99per vial£3.00per mgTesting evidence
Evidence status
Testing claimed
Manufacturer statement
"Certificate of analysis on every product"; product page says "Independent reports are published as we receive them — coverage varies by strength and lot" and "Testing by Janoshik Analytical, covering peptide content and purity."
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
10/45
Value
18/25
Product identity
13/15
Supplier transparency
3/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
7BPC-157 + TB-500 Blend 20-mg / owsa-bb-20mgOwsa Labs20 mg / vial£64.99per vial£3.25per mgTesting evidence
Evidence status
Testing claimed
Manufacturer statement
Certificate of analysis on every product; We hold 1 laboratory report for this compound. It covers the lot it names, so check the lot number on your vial against the list below. BPC-157 + TB-500 Blend – 20 mg | BB10/2025-04 | Janoshik Analytical | Verify at laboratory. Testing by Janoshik Analytical, covering peptide content and purity.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
10/45
Value
17/25
Product identity
13/15
Supplier transparency
3/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
8BPC-157 + TB-500 Blend 5 mgUK Peptides (ukpeptides.com)5 mg / vial£44.99per vial£9.00per mgTesting evidence
Evidence status
Testing claimed
Manufacturer statement
"99.1% HPLC purity · batch COA"; "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "Every batch is analyzed by an accredited third-party laboratory before it ships."; "Bioburden testing and LAL endotoxin assays are conducted per USP guidelines on a batch-sample basis."
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
Why this score?
Testing & analytical evidence
10/45
Value
2/25
Product identity
11/15
Supplier transparency
3/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.		Buy Now
#1

BPC-157 10mg + TB-500 10mgAscend Peptides UK

Why this score?
Testing & analytical evidence
39/45
Value
21/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
20 mg / vial
Testing evidence
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22
£2.50per mg
£49.99per pack
View AnalysisBuy Now
Product & testing details
Supplier
Ascend Peptides UK
Vials per pack
1
Price per vial
£49.99
Listing last checked
2026-09-22 11:39:13
Evidence status
Verified independent evidence
Manufacturer statement
Supplier COA page lists Janoshik-linked certificates for BPC-157 10mg and TB-500 10mg, and the product page states the bundle is intended for research use only.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
20260114
Batch-specific report
Recorded
Report date
2026-04-07
Evidence checked
2026-09-22
#2

BPC-157 / TB-500 Mix 20mgReta Research

Why this score?
Testing & analytical evidence
12/45
Value
24/25
Product identity
12/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
20 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
Supplied as a lyophilised 20mg blend, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK.
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£2.00per mg
£40.00per pack
View AnalysisBuy Now
Product & testing details
Supplier
Reta Research
Vials per pack
1
Price per vial
£40.00
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
Supplied as a lyophilised 20mg blend, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK.
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
#3

Wolverine Stack 20mgPepSource

Why this score?
Testing & analytical evidence
10/45
Value
18/25
Product identity
14/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
20 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity. Certificates are published per batch and searchable by lot code on our lab results page. This batch was independently tested by Janoshik Analytical.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£3.00per mg
£60.00per pack
View AnalysisBuy Now
Product & testing details
Supplier
PepSource
Vials per pack
1
Price per vial
£60.00
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity. Certificates are published per batch and searchable by lot code on our lab results page. This batch was independently tested by Janoshik Analytical.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
#4

Wolverine Stack 10mgPepSource

Why this score?
Testing & analytical evidence
10/45
Value
14/25
Product identity
14/15
Supplier transparency
10/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
10 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
"Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity"; "the certificate of analysis for the batch you receive is published on our lab results page"; "Purity: Verified by HPLC on every batch — the measured figure for your lot is published on its certificate of analysis"
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£4.00per mg
£40.00per pack
View AnalysisBuy Now
Product & testing details
Supplier
PepSource
Vials per pack
1
Price per vial
£40.00
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
"Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity"; "the certificate of analysis for the batch you receive is published on our lab results page"; "Purity: Verified by HPLC on every batch — the measured figure for your lot is published on its certificate of analysis"
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
#5

BPC-157 + TB-500 (Research Blend) — 10mgSPX Labs

Why this score?
Testing & analytical evidence
10/45
Value
17/25
Product identity
13/15
Supplier transparency
6/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
10 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
Analytical documentation available where testing has been performed; for batch SPX-BPCTB10-001 the site reports BPC-157 content 6.00 mg, TB-500 content 5.38 mg, and purity not reported.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£3.30per mg
£32.99per pack
View AnalysisBuy Now
Product & testing details
Supplier
SPX Labs
Vials per pack
1
Price per vial
£32.99
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
Analytical documentation available where testing has been performed; for batch SPX-BPCTB10-001 the site reports BPC-157 content 6.00 mg, TB-500 content 5.38 mg, and purity not reported.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
#6

BPC-157 + TB-500 Blend 10-mg / owsa-bb-10mgOwsa Labs

Why this score?
Testing & analytical evidence
10/45
Value
18/25
Product identity
13/15
Supplier transparency
3/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
10 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
"Certificate of analysis on every product"; product page says "Independent reports are published as we receive them — coverage varies by strength and lot" and "Testing by Janoshik Analytical, covering peptide content and purity."
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£3.00per mg
£29.99per pack
View AnalysisBuy Now
Product & testing details
Supplier
Owsa Labs
Vials per pack
1
Price per vial
£29.99
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
"Certificate of analysis on every product"; product page says "Independent reports are published as we receive them — coverage varies by strength and lot" and "Testing by Janoshik Analytical, covering peptide content and purity."
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
#7

BPC-157 + TB-500 Blend 20-mg / owsa-bb-20mgOwsa Labs

Why this score?
Testing & analytical evidence
10/45
Value
17/25
Product identity
13/15
Supplier transparency
3/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
20 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
Certificate of analysis on every product; We hold 1 laboratory report for this compound. It covers the lot it names, so check the lot number on your vial against the list below. BPC-157 + TB-500 Blend – 20 mg | BB10/2025-04 | Janoshik Analytical | Verify at laboratory. Testing by Janoshik Analytical, covering peptide content and purity.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£3.25per mg
£64.99per pack
View AnalysisBuy Now
Product & testing details
Supplier
Owsa Labs
Vials per pack
1
Price per vial
£64.99
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
Certificate of analysis on every product; We hold 1 laboratory report for this compound. It covers the lot it names, so check the lot number on your vial against the list below. BPC-157 + TB-500 Blend – 20 mg | BB10/2025-04 | Janoshik Analytical | Verify at laboratory. Testing by Janoshik Analytical, covering peptide content and purity.
Laboratory
Janoshik Analytical
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
#8

BPC-157 + TB-500 Blend 5 mgUK Peptides (ukpeptides.com)

Why this score?
Testing & analytical evidence
10/45
Value
2/25
Product identity
11/15
Supplier transparency
3/10
Label & listing transparency
5/5
Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.
Quantity
5 mg / vial
Testing evidence
Evidence status
Testing claimed
Manufacturer statement
"99.1% HPLC purity · batch COA"; "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "Every batch is analyzed by an accredited third-party laboratory before it ships."; "Bioburden testing and LAL endotoxin assays are conducted per USP guidelines on a batch-sample basis."
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22
£9.00per mg
£44.99per pack
View AnalysisBuy Now
Product & testing details
Supplier
UK Peptides (ukpeptides.com)
Vials per pack
1
Price per vial
£44.99
Listing last checked
2026-09-22 11:04:33
Evidence status
Testing claimed
Manufacturer statement
"99.1% HPLC purity · batch COA"; "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "Every batch is analyzed by an accredited third-party laboratory before it ships."; "Bioburden testing and LAL endotoxin assays are conducted per USP guidelines on a batch-sample basis."
Laboratory
Not recorded
Certification body
Not recorded
Batch
Not recorded
Batch-specific report
Not established in this record
Report date
Not recorded
Evidence checked
2026-09-22

What is BPC-157 + TB-500?

The category describes a blend of two separate research peptides: BPC-157 and material marketed as TB-500. “Wolverine blend” and “Wolverine stack” are market names, not standardised scientific formulations. UK supplier pages reviewed for nomenclature show that sellers can state different total amounts and per-component splits, so the category name alone does not establish ratio, total quantity, chemical form or testing evidence. [S19] [S20]

Do not infer a 1:1 ratio, per-component milligram amount or exact TB-500 identity from the word “Wolverine” or from a combined total mass.

BPC-157, TB-500 and thymosin beta-4 are not interchangeable labels

BPC-157 has a defined 15-amino-acid sequence. TB-500 is more problematic: analytical anti-doping research identified a marketed TB-500 preparation as N-terminally acetylated LKKTETQ, corresponding to thymosin beta-4 residues 17–23. Full-length thymosin beta-4 is a different 43-amino-acid molecule with its own clinical research programme. Evidence for full-length thymosin beta-4 should therefore be labelled as such and not presented as direct evidence for the short TB-500 fragment. [S5] [S6] [S7] [S8] [S9]

Name usedWhat the source actually describesHow to handle it
BPC-157Defined 15-amino-acid peptide; PubChem sequence GEPPPGKPADDAGLV.Use BPC-157 evidence only for BPC-157. [S5]
TB-5002012 analytical studies identified marketed TB-500 material as N-acetylated LKKTETQ / thymosin beta-4 residues 17–23.Require identity evidence for each listing; do not assume all supplier material is chemically identical. [S6] [S7]
Thymosin beta-4 / Tβ4Full-length 43-amino-acid endogenous peptide/protein used in human wound and ophthalmic trials.Do not relabel its human trial results as TB-500 evidence. [S8] [S9] [S10]
BPC-157 + TB-500 / Wolverine blendCommercial two-component blend name with no universal scientific formulation.Record both components, their amounts and evidence separately. [S19] [S20]

A supplier label that says only “TB-500” does not by itself prove whether the vial contains Ac-LKKTETQ, another thymosin-derived fragment, full-length thymosin beta-4 or a correctly identified material. Analytical documentation must resolve that question.

What does the research show?

The evidence must be separated into BPC-157, TB-500, full-length thymosin beta-4 and combination research. BPC-157 has a large preclinical literature but sparse human evidence. The exact Ac-LKKTETQ material associated with TB-500 has analytical and animal evidence but no established human therapeutic evidence. Full-length thymosin beta-4 has human clinical studies, but it is a different molecule. The BPC-157 + TB-500 pair has one recent controlled rat tendon study located in this research, and that study did not demonstrate an additive benefit for the combination. [S1] [S3] [S6] [S8] [S9]

BPC-157 alone

Most evidence is preclinical. Human musculoskeletal evidence is limited and uncontrolled, so animal healing findings should not be translated into established human benefit. [S2] [S3]

Mostly preclinical

TB-500

Direct research on material identified as Ac-LKKTETQ includes analytical characterisation and animal work. Human trials of full-length thymosin beta-4 are not human TB-500 trials. [S6] [S7] [S8] [S9]

Identity-sensitive evidence

Full-length thymosin beta-4

Human trials exist in areas such as venous ulcers and ophthalmic disease, using full-length thymosin beta-4 formulations. These studies are relevant background but cannot establish effects of TB-500. [S8] [S9] [S10]

Human evidence for a different molecule

The combination

A 2026 rat Achilles-tendon study directly compared control, BPC-157, TB-500 and the combination. The authors reported that combined treatment did not confer additional benefit over either agent alone. [S1]

Direct preclinical combination evidence
Research questionEvidence locatedInterpretation
Does BPC-157 improve tissue repair in humans?Sparse uncontrolled human reports plus extensive animal work.Not established by controlled human trials. [S2] [S3]
Has TB-500 itself been tested clinically in humans?No verified human therapeutic trial of the Ac-LKKTETQ TB-500 material was located.Do not substitute full-length Tβ4 trials. [S6] [S7]
Has full-length thymosin beta-4 been tested in humans?Yes, including wound and ophthalmic trials.Different molecule; results do not establish TB-500 effects. [S8] [S9] [S10]
Has BPC-157 + TB-500 been tested together?Yes, in a 32-rat Achilles-tendon model.Direct combination evidence is preclinical; no additive benefit was found. [S1]
Has a commercial Wolverine blend been tested?No controlled human trial of an exact marketed blend was located.Commercial formulation efficacy and safety remain unestablished. [S1] [S2]

The existence of a combination study does not support a synergy claim. In the direct 2026 rat experiment, the authors explicitly reported no additional benefit from combined treatment compared with either peptide alone. [S1]

What the direct BPC-157 + TB-500 study actually found

Biçer and colleagues used 32 male Sprague-Dawley rats after standardised Achilles tendon transection and repair. Eight animals were assigned to each of four groups: control, BPC-157, TB-500 and combined BPC-157 + TB-500. After four weeks, the investigators assessed biomechanical failure load, histology, collagen organisation and collagen I/III expression. Maximum load to failure was higher in the BPC-157 and TB-500 groups than control, but statistical significance was reached for TB-500. Total Movin scores were significantly lower in TB-500 and combination groups versus control. The authors nevertheless concluded that combined treatment did not confer additional benefit over either agent alone. [S1]

FeatureStudy detailLimitation
Species and model32 male Sprague-Dawley rats with Achilles tendon transection and repair; 8 per group.Animal surgical model; cannot establish human healing outcomes. [S1]
GroupsControl, BPC-157, TB-500 and BPC-157 + TB-500 combination.Single experimental setting and short follow-up. [S1]
Key findingsTB-500 reached significance for maximum load to failure; TB-500 and combination groups had lower total Movin scores versus control.Different endpoints did not all move in the same way. [S1]
Combination conclusionThe authors reported no additional benefit from the combination over either agent alone.Does not rule out every possible interaction, but it does not support a proven synergy claim. [S1]

Study quantities and route are recorded in the research file for scientific provenance but are not reproduced here as consumer instructions.

Human evidence is limited and does not validate the commercial blend

The clearest human report touching both names is a 2021 retrospective knee-pain chart review. Seventeen patients had been treated; 16 were reached by telephone. Twelve had received BPC-157 alone and four had received BPC-157 plus thymosin beta-4. Three of the four combination recipients reported significant improvement. The study had no control group, no blinding and no validated functional outcome instruments, and it used thymosin beta-4 rather than a chemically verified TB-500 fragment. It therefore cannot establish efficacy, comparative benefit or safety of a BPC-157 + TB-500 commercial blend. [S2]

BPC-157 human evidence

Published human evidence is small and methodologically weak compared with the preclinical literature. The 2025 systematic review highlighted the lack of clinical safety data and the predominance of animal evidence. [S3]

Very limited human evidence

Four combination recipients

In the 2021 retrospective knee series, four people received BPC-157 plus TB4 and three reported improvement. There was no control group and no validated outcome instrument. [S2]

Uncontrolled retrospective evidence

Not a verified TB-500 trial

The paper describes thymosin beta-4 (TB4). It does not chemically establish that the second peptide was the Ac-LKKTETQ fragment identified in analytical TB-500 literature. [S2] [S6]

Identity limitation

A positive self-reported outcome in a four-person uncontrolled subgroup is not evidence that the marketed 'Wolverine' blend accelerates healing in humans.

Registered trials must be separated by compound identity

Clinical trial registries contain BPC-157 and full-length thymosin beta-4 records, but these are not trials of the commercial BPC-157 + TB-500 blend. The older BPC-157 phase 1 record NCT02637284 has an unknown status and no posted results. Full-length thymosin beta-4 has multiple registered programmes, including RGN-259 ophthalmic trials; these do not test TB-500. No genuine registered human trial of the exact BPC-157 + TB-500 blend was located in the searches performed for this review. [S10] [S11]

RegistryCompound actually studiedStatus / relevance
NCT02637284BPC-157 / Bepecin / PCO-02Phase 1 healthy-volunteer safety/PK record; status unknown; no posted results. [S11] [S12]
NCT02600429RGN-259 containing full-length thymosin beta-4Terminated phase 3 neurotrophic-keratopathy trial; results posted; not TB-500. [S9] [S10]
Exact BPC-157 + TB-500 blendNo genuine registry record located in targeted searches.No registered human blend result available. [S1] [S2]

Registry presence is not proof of efficacy, and a trial of full-length thymosin beta-4 must not be counted as a TB-500 trial.

Pharmacokinetic evidence does not produce a single profile for the blend

BPC-157 has published pharmacokinetic work in rats and beagle dogs, where prototype BPC-157 showed an elimination half-life under 30 minutes after the studied administrations and was rapidly metabolised into smaller peptide fragments. That is animal evidence, not a validated human half-life. For TB-500, analytical animal work has identified the Ac-LKKTETQ parent and metabolites in equine samples. These separate findings cannot be combined into a pharmacokinetic profile for a BPC-157 + TB-500 blend. [S4] [S7]

BPC-157

Rat and beagle-dog PK work reported rapid disappearance of prototype BPC-157 and metabolism into smaller peptide fragments. [S4]

Animal PK

TB-500

Equine anti-doping research detected N-acetylated LKKTETQ and metabolites after administration. This is animal analytical evidence, not human clinical PK. [S7]

Equine analytical evidence

Blend

No validated human pharmacokinetic study of the exact combined formulation was located. [S1] [S2]

Unknown

Do not publish a single 'half-life of the Wolverine blend'. The ingredients are separate molecules and the available pharmacokinetic evidence is formulation- and species-specific.

Safety evidence is incomplete, especially for the combined product

The direct rat combination study was designed around tendon healing rather than long-term toxicology. Published human combination evidence is a small uncontrolled retrospective report and cannot establish safety. For BPC-157, FDA's 2026 review noted limited clinical information, an uncompleted/unknown-status phase 1 registry record and incomplete safety characterisation. For TB-500, human safety claims are further complicated by the frequent substitution of full-length thymosin beta-4 data for the shorter marketed fragment. [S1] [S2] [S12] [S13]

No blend safety trial

No controlled human safety trial of an exact BPC-157 + TB-500 commercial blend was located. [S1] [S2]

Major evidence gap

BPC-157 uncertainty

FDA's 2026 compounding review describes limited human data and no posted results for the registered phase 1 study located in its search. [S12] [S13]

Limited human safety data

TB-500 uncertainty

Human data on full-length thymosin beta-4 cannot define the safety of Ac-LKKTETQ TB-500 or of supplier-labelled TB-500 material. [S6] [S8] [S9]

Identity-dependent

Commercial formulation uncertainty

Co-formulation introduces additional questions about identity, amount, purity, degradation and batch consistency that clinical studies of separate ingredients do not answer. [S19] [S20]

Product-level evidence needed

Absence of a documented adverse event in a small study is not proof of long-term safety. Safety conclusions must stay within the population, molecule and formulation actually studied.

UK regulatory and anti-doping context

MHRA guidance states that human medicines require appropriate authorisation, with separate regulated provisions for certain unlicensed medicines supplied to meet an individual patient's clinical need. Targeted MHRA product-information searches did not locate a UK-authorised medicine named BPC-157 or TB-500 as of 2026-09-22, so this page does not present either as an authorised UK medicine. In sport, WADA's 2026 list places BPC-157 under S0 Non-Approved Substances and names thymosin-β4 and its derivatives, including TB-500, under S2.3. UK Anti-Doping explains that WADA-listed substances may be prohibited at all times or in competition; both of these categories apply at all times. [S14] [S15] [S16] [S17] [S18]

UK medicines

No UK-authorised medicine named BPC-157 or TB-500 was located in the targeted MHRA product-information search. This is not a blanket legal classification of every research product or transaction. [S16] [S17] [S18]

UK context

BPC-157 in sport

BPC-157 is prohibited under WADA S0 Non-Approved Substances. [S14] [S15]

Prohibited at all times

TB-500 in sport

WADA S2.3 names thymosin-β4 and its derivatives, including TB-500. [S14] [S15]

Prohibited at all times

Anti-doping status is a sport-governance rule, not a statement that every product carrying these names has been chemically verified.

How to interpret Wolverine-blend listings

The commercial name does not define the contents. UK supplier pages observed for this review use the 'Wolverine' label for BPC-157 + TB-500 products and disclose different total pack descriptions. A credible comparison therefore needs the amount and identity of each component rather than a combined milligram total. Supplier claims about purity, testing or tissue repair must be checked against the actual report and must not be used as clinical evidence. [S19] [S20]

Record both component amounts

A total blend mass does not state how much is BPC-157 and how much is TB-500. Store both labelled quantities separately. [S19] [S20]

No inferred split

Resolve TB-500 identity

The comparison should distinguish a verified Ac-LKKTETQ fragment from full-length thymosin beta-4, another fragment or an unresolved supplier label. [S6] [S7]

Identity required

Keep testing claims narrow

A supplier purity or COA claim does not establish human safety, efficacy or synergy, and a blend report should make clear whether both components were identified and quantified. [S19] [S20]

Testing ≠ clinical proof
Listing fieldWhat should be capturedIf missing
BPC-157 amountExplicit amount for BPC-157 tied to the product label.Leave unknown; do not divide total blend mass. [S19] [S20]
TB-500 amountExplicit amount for the TB-labelled component.Leave unknown; do not assume a 1:1 ratio. [S19] [S20]
TB-500 identityAc-LKKTETQ / Tβ4(17–23), full-length Tβ4, another fragment or unresolved.Show identity not confirmed. [S6] [S7]
Analytical evidenceBatch-specific evidence showing what was tested and whether both components were identified/quantified.Do not convert a generic purity claim into verified blend identity. [S19] [S20]
Clinical claimEvidence must match the actual combination and formulation.Do not transfer single-ingredient or full-length Tβ4 findings to the blend. [S1] [S2] [S8] [S9]

Check the identity and labelled amount of each component separately. A combined milligram total does not establish the amount of BPC-157 or TB-500.

Frequently asked questions

What is the Wolverine blend?

It is a marketing name commonly used for a BPC-157 + TB-500 research blend. The name does not define a standard ratio, total mass, chemical form or verified TB-500 identity. [S19] [S20]

Have BPC-157 and TB-500 actually been studied together?

Yes. A 2026 controlled study tested BPC-157, TB-500 and their combination in a rat Achilles-tendon repair model. The authors reported that the combined treatment did not provide additional benefit over either agent alone. [S1]

Has the BPC-157 + TB-500 blend been proven to accelerate healing in humans?

No. No controlled human trial of an exact commercial blend was located. A small retrospective knee-pain report included four people who received BPC-157 plus thymosin beta-4, but it had no control group and did not establish the second peptide as the Ac-LKKTETQ TB-500 fragment. [S2] [S6]

Is TB-500 the same as thymosin beta-4?

Not necessarily. Analytical studies identified material marketed as TB-500 as an N-terminally acetylated seven-amino-acid fragment, Ac-LKKTETQ, corresponding to thymosin beta-4 residues 17–23. Full-length thymosin beta-4 is a different 43-amino-acid molecule. [S6] [S7]

Can human thymosin beta-4 trials be used as evidence for TB-500?

They can provide biological background, but they should not be presented as direct TB-500 evidence. Trials such as venous-ulcer and RGN-259 ophthalmic studies used full-length thymosin beta-4 formulations. [S8] [S9] [S10]

Does the research show that BPC-157 and TB-500 are synergistic?

No proven synergy has been established. In the direct 2026 rat comparison, the authors specifically reported that the combination did not confer additional benefit over either agent alone. [S1]

What human evidence exists for BPC-157?

Published human evidence is limited and methodologically weak compared with the animal literature. The 2025 systematic review highlighted sparse human musculoskeletal data and a lack of established clinical safety evidence. [S2] [S3]

Is BPC-157 + TB-500 an approved medicine in the UK?

Targeted MHRA product-information searches did not locate a UK-authorised medicine named BPC-157 or TB-500 as of 22 September 2026. MHRA guidance also recognises specific regulated routes for certain unlicensed medicines, so this should not be simplified into a blanket legal statement about every research listing. [S16] [S17] [S18]

Are BPC-157 and TB-500 banned in sport?

For athletes subject to WADA rules, yes. BPC-157 is prohibited under S0 Non-Approved Substances, and thymosin-β4 and its derivatives including TB-500 are listed under S2.3. These categories are prohibited at all times. [S14] [S15]

Can a 10 mg Wolverine blend be assumed to contain 5 mg of each peptide?

No. A combined total does not establish the per-component split. Each ingredient amount must be taken from the actual product label or supporting documentation; if it is not disclosed, it should remain unknown. [S19] [S20]

Sources & methodology

We separate animal models, observational human studies and ongoing trials. Scientific evidence is assessed independently of future supplier documentation. How we verify testing →

Page updated: Sources checked: 22 September 2026

Testing evidence in this comparison

  • Testing claimed: 7
  • Verified independent evidence: 1

What does Wolverine (BPC-157 + TB-500) cost?

Lowest: £2.00 / mg · Median: £3.12 / mg · Highest: £9.00 / mg